Techno Medica Co., Ltd.

Tokyo Stock Exchange 6678.T

Techno Medica Co., Ltd. EBITDA Margin for the year ending March 31, 2024: 18.98%

Techno Medica Co., Ltd. EBITDA Margin is 18.98% for the year ending March 31, 2024, a 1.17% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

Techno Medica Co., Ltd. EBITDA Margin for the year ending March 31, 2023 was 18.76%, a -6.80% change year over year.
Techno Medica Co., Ltd. EBITDA Margin for the year ending March 31, 2022 was 20.13%, a 4.16% change year over year.
Techno Medica Co., Ltd. EBITDA Margin for the year ending March 31, 2021 was 19.33%, a 40.27% change year over year.
Techno Medica Co., Ltd. EBITDA Margin for the year ending March 31, 2020 was 13.78%, a -20.66% change year over year.

Key data

Date	EBITDA Margin	EBIT Margin	Depreciation and Amortization	EBIT

Tokyo Stock Exchange: 6678.T

Techno Medica Co., Ltd.

CEO	Mr. Masatomo Saneyoshi
IPO Date	March 12, 2007
Location	Japan
Headquarters	5-5-1, Nakamachidai
Employees	237
Sector	Healthcare
Industries Medical Instruments 3D Printing Biotechnology Chemicals & Advanced Materials Cleaning Supplies Hardware & Electronics Personal Care Plastics

Description

Techno Medica Co., Ltd. engages in the research and development, manufacture, sale, import, and export of in-vitro diagnostic analyzers in Japan. The company offers test tube preparation, automatic urine aliquot, RFID specimen management, and RFID blood transfusion management, as well as blood gas, electrolyte, Erythrocyte Sedimentation Rate, nutrient, sugar and acid, and urine chemistry analyzers; electronic medical charts and pre-analytical instruments; and consumables and after sales services. Techno Medica Co., Ltd. was incorporated in 1987 and is headquartered in Yokohama, Japan.

Key trends

Past 5 years